Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?

European Journal of Pharmacology

Volumn 700, Issue 1-3, 2013, Pages 23-31

  Hemmeryckx, Bianca ^a   Hoylaerts, Marc F ^a   Gallacher, David J ^d   Rong Lu, Hua ^d   Himmelreich, Uwe ^b   D'Hooge, Jan ^c   Swinnen, Melissa ^c   Lijnen, Henri R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Catholic University of Leuven   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Adiposity; Cardiac function; Genetic Akita mice; PPAR ; Rosiglitazone

Indexed keywords

AVANDEMET; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BODY FAT DISTRIBUTION; CARDIOVASCULAR PARAMETERS; CELL INFILTRATION; CELL SIZE; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; FRACTIONAL SHORTENING; GENETIC PREDISPOSITION; HEART EJECTION FRACTION; HEART FUNCTION; HEART OUTPUT; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHY; INTRAVENTRICULAR SEPTUM THICKNESS; LIPID DIET; LIPOGENESIS; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ADIPOSITY; ANIMALS; DIABETES MELLITUS; GENOTYPE; HEART; HETEROZYGOTE; HYPERTROPHY; MALE; MICE; THIAZOLIDINEDIONES;

EID: 84872166617     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.11.062     Document Type: Article

References (50)

1. H. Bugger, and E.D. Abel Rodent models of diabetic cardiomyopathy Dis. Model. Mech. 2 2009 454 466
2. M.C. Carmona, K. Louche, M. Nibbelink, B. Prunet, A. Bross, M. Desbazeille, C. Dacquet, P. Renard, L. Casteilla, and L. Pénicaud Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice Int. J. Obes. (Lond) 29 2005 864 871 (Pubitemid 40897026)
3. J.H. Choi, A.S. Banks, J.L. Estall, S. Kajimura, P. Boström, D. Laznik, J.L. Ruas, M.J. Chalmers, T.M. Kamenecka, M. Blüher, P.R. Griffin, and B.M. Spiegelman Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 Nature 466 2010 451 456
4. S. Cinti, G. Mitchell, G. Barbatelli, I. Murano, E. Ceresi, E. Faloia, S. Wang, M. Fortier, A.S. Greenberg, and M.S. Obin Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans J. Lipid Res. 46 2005 2347 2355 (Pubitemid 41532523)
5. P.J. Declerck, M. Verstreken, and D. Collen Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice Thromb. Haemost. 74 1995 1305 1309
6. W.T. Festuccia, M. Laplante, S. Brûlé, V.P. Houde, A. Achouba, D. Lachance, M.L. Pedrosa, M.E. Silva, R. Guerra-Sá, J. Couet, M. Arsenault, A. Marette, and Y. Deshaies Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation J. Mol. Cell. Cardiol. 47 2009 85 95
7. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, C. Worrall, and J.A. Kelman Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone J. Am. Med. Assoc. 304 2010 411 418
8. B. Hemmeryckx, M.F. Hoylaerts, and H.R. Lijnen Effect of premature aging on murine adipose tissue Exp. Gerontol. 3 2012 256 262
9. B. Hemmeryckx, U. Himmelreich, M.F. Hoylaerts, and H.R. Lijnen Impact of clock gene Bmal1 deficiency on nutritionally induced obesity in mice Obesity (Silver Spring) 19 2011 659 661
10. E.G. Hong, D.Y. Jung, H.J. Ko, Z. Zhang, Z. Ma, J.Y. Jun, J.H. Kim, A.D. Sumner, T.C. Vary, T.W. Gardner, S.K. Bronson, and J.K. Kim Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling Am. J. Physiol. Endocrinol. Metab. 293 2007 E1687 E1696
11. R.L. Hoo, W.S. Chow, M.H. Yau, A. Xu, A.W. Tso, H.F. Tse, C.H. Fong, S. Tam, L. Chan, and K.S. Lam Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production Arterioscler. Thromb. Vasc. Biol. 27 2007 2777 2782 (Pubitemid 350158936)
12. O.J. How, T.S. Larsen, A.D. Hafstad, A. Khalid, E.S. Myhre, A.J. Murray, N.T. Boardman, M. Cole, K. Clarke, D.L. Severson, and E. Aasum Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice Arch. Physiol. Biochem. 113 2007 211 220
13. D.G. Johns, Z. Ao, M. Eybye, A. Olzinski, M. Costell, S. Gruver, S.A. Smith, S.A. Douglas, and C.H. Macphee Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat J. Pharmacol. Exp. Ther. 315 2005 1020 1027 (Pubitemid 41637837)
14. N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R.E. Buckingham, B. Staels, and A. Bril Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury Diabetes 51 2002 1507 1514 (Pubitemid 34826618)
15. J.K. Kim, J.J. Fillmore, O. Gavrilova, L. Chao, T. Higashimori, H. Choi, H.-J. Kim, C. Yu, Y. Chen, X. Qu, M. Haluzik, M.L. Reitman, and G.I. Shulman Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice Diabetes 52 2003 1311 1318 (Pubitemid 36666182)
16. Y.J. Koh, B.H. Park, J.H. Park, J. Han, I.K. Lee, J.W. Park, and G.Y. Koh Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues Exp. Mol. Med. 41 2009 880 895
17. M. Komajda, J.J. McMurray, H. Beck-Nielsen, R. Gomis, M. Hanefeld, S.J. Pocock, P.S. Curtis, N.P. Jones, and P.D. Home Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial Eur. Heart J. 31 2010 824 831
18. M.R. MacDonald, M.C. Petrie, P.D. Home, M. Komajda, N.P. Jones, H. Beck-Nielsen, R. Gomis, M. Hanefeld, S.J. Pocock, P.S. Curtis, and J.J. McMurray Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD) study Diabetes Care 34 2011 1394 1396
19. D.H. MacIver, and M.J. Dayer An alternative approach to understanding the pathophysiological mechanisms of chronic heart failure Int. J. Cardiol. 154 2012 102 110
20. J. Mersmann, N. Tran, P.A. Zacharowksi, D. Grotemeyer, and K. Zacharowski Rosiglitazone is cardioprotective in a murine model of myocardial I/R Shock 30 2008 64 68
21. I. Mikaelian, A. Buness, G. Hirkaler, R. Fernandes, D. Coluccio, W. Geng, T. Visalli, M.O. Bachynsky, W. Berkofsky-Fessler, C. Kanwal, H. Hilton, R. Nicklaus, J.C. Hoflack, M. Dunn, M. Sanders, M. Giron, B.W. Boyle, T. Singer, and L.S. Dick Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone Toxicol. Lett. 201 2011 110 115
22. Y. Miyazaki, L. Glass, C. Triplitt, M. Matsuda, K. Cusi, A. Mahankali, S. Mahankali, L.J. Mandarino, and R.A. DeFronzo Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients Diabetologia 44 2001 2210 2219 (Pubitemid 34015474)
23. R.F. Morrison, and S.R. Farmer Hormonal signaling and transcriptional control of adipocyte differentiation J. Nutr. 130 2000 3116S 3121S (Pubitemid 32005352)
24. I. Murano, G. Barbatelli, V. Parisani, C. Latini, G. Muzzonigro, M. Castellucci, and S. Cinti Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice J. Lipid Res. 49 2008 1562 1568
25. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, E.S. Horton, M. Le Winter, D. Porte, C.F. Semenkovich, S. Smith, L.H. Young, and R. Kahn Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2003 2941 2948 (Pubitemid 37517824)
26. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch. Intern. Med. 170 2010 1191 1201
27. R.M. Ortiz, C.E. Wade, D.P. Costa, and C.L. Ortiz Renal responses to plasma volume expansion and hyperosmolality in fasting seal pups Am. J. Physiol. Regul. Integr. Comp. Physiol 282 2002 R805 R817
28. C. Pieri, R. Testa, M. Marra, A.R. Bonfigli, S. Manfrini, and I. Testa Age-dependent changes of serum oxygen radical scavenger capacity and haemoglobin glycosylation in non-insulin-dependent diabetic patients Gerontology 47 2001 88 92 (Pubitemid 32260818)
29. R. Pop-Busui, E. Oral, D. Raffel, J. Byun, V. Bajirovic, A. Vivekanandan-Giri, A. Kellogg, S. Pennathur, and M.J. Stevens Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus Metabolism 58 2009 989 994
30. M. Potenza, S. Gagliardi, L. De Benedietis, A. Zigrino, E. Tiravanti, G. Colantuono, A. Federici, L. Lorusso, V. Benagiano, M.J. Quon, and M. Montagnami Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature Am. J. Physiol. Endocrinol. Metab. 297 2009 E685 E694
31. C.E. Quinn, P.K. Hamilton, C.J. Lockhart, and G.E. McVeigh Thiazolidinediones: effects on insulin resistance and the cardiovascular system Br. J. Pharmacol. 153 2008 636 645 (Pubitemid 351271751)
32. M.N. Rao, R. Mullangi, K. Katneni, B. Ravikanth, A.P. Babu, U.P. Rani, M.U. Naidu, N.R. Srinivas, and R. Rajagopalan Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone J. Clin. Pharmacol. 42 2002 670 675 (Pubitemid 34547451)
33. D.A. Rees, and J.C. Alcolado Animal models of diabetes mellitus Diabet. Med. 22 2005 359 370 (Pubitemid 40516231)
34. M. Reynolds Plasma and blood volume in the cow using the T-1824 hematocrit method Am. J. Physiol. 173 1953 421 427
35. C. Savoia, T. Ebrahimian, C.A. Lemarié, P. Paradis, M. Iglarz, F. Amiri, D. Javeshgani, and E.L. Schiffrin Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1 Clin. Sci. 118 2010 583 592
36. N. Selvaraj, Z. Bobby, and M.G. Sridhar Increased glycation of hemoglobin in chronic renal failure: potential role of oxidative stress Arch. Med. Res. 39 2008 277 284 (Pubitemid 351221153)
37. E. Selvin, J. Coresh, J. Jordahl, L. Boland, and M.W. Steffes Stability of haemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade Diabet. Med. 22 2005 1726 1730 (Pubitemid 43046475)
38. R.J. Sidell, M.A. Cole, N.J. Draper, M. Desrois, R.E. Buckingham, and K. Clarke Thiozolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart Diabetes 51 2002 1110 1117 (Pubitemid 34438357)
39. R. Stienstra, C. Duval, S. Keshtkar, J. van der Laak, S. Kersten, and M. Müller Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue J. Biol. Chem. 283 2008 22620 22627
40. J. Stypmann, M.A. Engelen, C. Troatz, M. Rothenburger, L. Eckardt, and K. Tiemann Echocardiographic assessment of global left ventricular function in mice Lab. Anim. 43 2009 127 137
41. C. Tikellis, K.A. Jandeleit-Dahm, K. Sheehy, A. Murphy, J. Chin-Dusting, D. Kling, E. Sebokova, M.E. Cooper, J. Mizrahi, and K.J. Woollard Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules Atherosclerosis 199 2008 55 64
42. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 1994 1147 1156
43. M. Van Hul, and H.R. Lijnen A functional role of gelatinase A in the development of nutritionally induced obesity in mice J. Thromb. Haemost. 6 2008 1198 1206 (Pubitemid 351863377)
44. X. Wang, X. Liu, Y. Zhan, E.R. Lavallie, L. Diblasio-Smith, L. Collins-Racie, W.M. Mounts, J.L. Rutkowski, X. Xu, I. Goltsman, Z. Abassi, J. Winaver, and G.Z. Feuerstein Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation J. Pharmacol. Exp. Ther. 334 2010 820 829
45. T.M. Willson, M.H. Lambert, and S.A. Kliewer Peroxisome proliferator-activated receptor gamma and metabolic disease Annu. Rev. Biochem. 70 2001 341 367 (Pubitemid 32662214)
46. C. Yang, T.J. Chang, J.C. Chang, M.W. Liu, T.Y. Tai, W.H. Hsu, and L.M. Chuang Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway Diabetes 50 2001 2598 2602 (Pubitemid 33642780)
47. X.Q. Yang, and A.F. Chen High-cholesterol diet augments endothelial dysfunction via elevated oxidative stress and reduced tetrahydrobiopterin in Ins2(Akita) mice, an autosomal dominant mutant type 1 diabetic model Clin. Exp. Pharmacol. Physiol. 36 2009 764 769
48. M. Yoshioka, T. Kayo, T. Ikeda, and A. Koizumi A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice Diabetes 46 1997 887 894 (Pubitemid 27188269)
49. T.L. Yue, W. Bao, J.L. Gu, J. Cui, L. Tao, X.L. Ma, E.H. Ohlstein, and B.M. Jucker Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury Diabetes 54 2005 554 562
50. T.L. Yue, J. Chen, W. Bao, P.K. Narayanan, A. Bril, W. Jiang, P.G. Lysko, J.L. Gu, R. Boyce, D.M. Zimmerman, T.K. Hart, R.E. Buckingham, and E.H. Ohlstein In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 2001 2588 2594 (Pubitemid 33104798)